← Browse by Condition
Medical Condition
chronic spontaneous urticaria
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 3
NCT05677451 Phase 3
Recruiting
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Enrollment
100 pts
Location
United States, Argen...
Sponsor
Novartis Pharmaceuticals
NCT07316114
Recruiting
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Enrollment
400 pts
Location
United States
Sponsor
Sanofi